| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9145519 | Cardiovascular Revascularization Medicine | 2005 | 6 Pages |
Abstract
Bivalirudin, as a single antithrombotic agent during PCI and VBT, is associated with significantly lower postprocedural CPK-MB elevation, minor bleeding complications, 30-day non-Q-wave MI rates, and a trend toward lower major bleeding and in-hospital MACE when compared with eptifibatide.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
Pramod Kuchulakanti, Roswitha Wolfram, Rebecca Torguson, Seung-Woon Rha, Edouard Cheneau, Leonardo Clavijo, William W. Chu, Ellen E. Pinnow, Daniel Canos, Lowell F. Satler, William O. Suddath, Augusto D. Pichard, Kenneth M. Kent, Ron Waksman,